Home Clinical Topics FDA approves expanded use of Isentress in children and adolescents

FDA approves expanded use of Isentress in children and adolescents

The U.S. Food and Drug Administration has approved Isentress (raltegravir) for use with other antiretroviral drugs for the treatment of HIV-1 infection for children and adolescents ages 2 to 18. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here